Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation
Abstract The increased incidence of secondary hematologic malignancies (SHM) is a well-known, potentially fatal, complication after cancer treatment. It is unknown if patients with ductal carcinoma in situ (DCIS) of the breast treated with external beam radiotherapy (RT) and who survive long-term ha...
Guardado en:
Autores principales: | Kang Wang, Zhuyue Li, Xingxing Chen, Jianjun Zhang, Yongfu Xiong, Guochao Zhong, Yang Shi, Qing Li, Xiang Zhang, Hongyuan Li, Tingxiu Xiang, Theodoros Foukakis, Tomas Radivoyevitch, Guosheng Ren |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8300914d0d4442d3a990b33db2880489 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Mutational signatures of ionizing radiation in second malignancies
por: Sam Behjati, et al.
Publicado: (2016) -
Concurrent ductal carcinoma in-situ and malignant phyllodes with tp53 mutation in an 11-year-old
por: Cameron F. Leveille, et al.
Publicado: (2021) -
Cytokine Expression of Lung Bacterial Infection in Newly Diagnosed Adult Hematological Malignancies
por: Zengzheng Li, et al.
Publicado: (2021) -
Immunological and hematological outcomes following protracted low dose/low dose rate ionizing radiation and simulated microgravity
por: Amber M. Paul, et al.
Publicado: (2021) -
Unmasking the immune microecology of ductal carcinoma in situ with deep learning
por: Priya Lakshmi Narayanan, et al.
Publicado: (2021)